China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced a strategic license agreement with Abbott Laboratories (NYSE: ABT). The agreement grants the US multinational company exclusive or semi-exclusive development and commercialization rights to four biosimilars and one novel biologic drug in 69 emerging countries and regions. The deal, for which no financial details were disclosed, covers Asia, Latin America and the Caribbean, as well as the Middle East and North Africa.
Building on Existing Partnership
This accord is built on an existing oncology biosimilar partnership between Henlius and Abbott. Under the terms of the agreement, the first batch of molecule candidates is expected to hit the market in 2027. The remaining drugs are still undergoing clinical development and regulatory filing processes. Abbott will be responsible for market registration and promotion of the cooperative products within the specified territories.
Manufacturing and Production
Henlius will manufacture these drugs at its GMP-aligned production base located in Shanghai. This strategic partnership leverages Abbott’s extensive global reach and commercial capabilities, combined with Henlius’s expertise in biosimilar development and manufacturing, to bring these important therapies to patients in emerging markets.-Fineline Info & Tech
